Skip to content

A Randomized, Double-Blind, Parallel-Controlled, Multicenter Clinical Trial of Xiao'er Jianpi Granules for the Treatment of Functional Dyspepsia in Children (Spleen Deficiency with Food Stagnation Syndrome)

A Randomized, Double-Blind, Parallel-Controlled, Multicenter Clinical Trial of Xiao'er Jianpi Granules for the Treatment of Functional Dyspepsia in Children (Spleen Deficiency with Food Stagnation Syndrome)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002170
Enrollment
Unknown
Registered
2025-11-08
Start date
2024-10-08
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Functional Dyspepsia

Interventions

Experimental Group:For children aged 4-6 years: Children's Jianpi Granules, 2.5 g per sachet, 1 sachet per dose, 3 times a day, taken orally 30 minutes before meals. For children aged 7-12 years: Chi
Control Group:For children aged 4 to 6 years: Pediatric Jianpi Granule Simulant, 2.5g per sachet, 1 sachet per dose, three times a day, taken orally 30 minutes before meals. For children aged 7 to 12

Sponsors

Shanghai City Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
4 Years to 12 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for functional dyspepsia in children and the PDS subtype diagnostic criteria; (2) Meets the diagnostic criteria for spleen deficiency with food stagnation in traditional Chinese medicine; (3) During the run-in period, the main symptom score on the PDS main symptom scale is =2 points for 1 or more main symptoms; (4) Age is between 4 and 12 years old (inclusive); (5) For children under 8 years old, the legal guardian provides informed consent and signs the informed consent form; for children 8 years old or older, both the child and the legal guardian provide informed consent and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) The child patient has comorbid irritable bowel syndrome, functional abdominal pain, functional constipation, and upper abdominal pain syndrome, among other clinical conditions; (2) The child patient had a history of prolonged improper feeding or picky eating prior to the onset of the disease; (3) The child patient has comorbid organic diseases of the digestive system, or digestive tract symptoms caused by other related diseases; (4) The child patient has a history of gastric or abdominal surgery (appendectomy excluded); (5) The child patient has comorbid severe primary diseases of the heart, liver, kidneys, or hematopoietic system, severe pulmonary infections, or other life-threatening severe diseases (e.g., malignant tumors); (6) The child patient needs to take non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, or antidepressants during the study period, which may cause symptoms of indigestion; (7) The child patient has used Chinese medicine (including Chinese herbal decoctions), Western medicine, gut microbiota agents, digestive health supplements, or acupuncture, massage, and patch therapy for the treatment of functional dyspepsia during the run-in period; (8) The child patient has an allergy to the investigational drug or its components; (9) The child patient has a history of cranial trauma within the past 3 months; (10) The child patient has participated in other clinical trials within the past 1 month; (11) The child patient has elevated liver function (AST, ALT) or renal function (Scr) levels exceeding the upper limit of normal values; (12) Other conditions or circumstances, as judged by the investigator, that may reduce the likelihood of enrollment or complicate the enrollment process, such as unstable living conditions, unstable emotions of the child or family members, or transportation difficulties, which may lead to non-compliance with the protocol or affect the evaluation of the study.

Design outcomes

Primary

MeasureTime frame
The total score of main symptoms (postprandial bloating discomfort or early satiety) in PDS (Postprandial Distress Syndrome) compared to baseline decrease.;

Secondary

MeasureTime frame
The total score of the main symptoms (post-meal bloating discomfort or early satiety) in PDS (Postprandial Distress Syndrome) decreased compared to the baseline value.;Response Rate to the Efficacy of Postprandial Distress Syndrome (PDS);Disappearance rate of single clinical symptoms in PDS (Postprandial Distress Syndrome);The decrease in the total score of the Traditional Chinese Medicine (TCM) syndrome scale compared to baseline.;The efficacy rate of traditional Chinese medicine syndromes;The disappearance rate of individual symptoms.;

Countries

China

Contacts

Public ContactXue Zheng

Shanghai City Hospital of Traditional Chinese Medicine

xz695@163.com18116070951

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026